Peripheral neuropathy is among the most prevalent neurological conditions worldwide, yet one of the most therapeutically neglected. An estimated 20–30 million Americans live with some form of peripheral nerve damage, with diabetic neuropathy alone accounting for roughly half of all cases. Globally, the number exceeds 200 million when chemotherapy-induced peripheral neuropathy (CIPN), HIV-associated neuropathy, alcoholic neuropathy, and idiopathic small-fiber neuropathy are included. The clinical picture is distressingly familiar: distal-to-proximal numbness, burning or electric-shock pain, loss of proprioception, and, in advanced cases, foot ulceration and amputation. Standard pharmacotherapy — gabapentin, pregabalin, duloxetine, and topical capsaicin or lidocaine — provides clinically meaningful relief for perhaps 30–40% of patients, and even among responders, the effect is often partial. None of these agents reverse the underlying axonal degeneration or demyelination. Mesenchymal stem cell (MSC) therapy has entered this gap with a mechanistically attractive proposition: rather than suppressing pain signals, it aims to repair the damaged nerve fibers, restore myelin integrity, and recalibrate the neuroinflammatory microenvironment that perpetuates neuropathic pain [1].

The Biology of Peripheral Nerve Damage

Peripheral nerves are fragile structures. Unlike central nervous system neurons, which are insulated by oligodendrocytes, peripheral axons depend on Schwann cells for myelination and trophic support. When a peripheral nerve is injured — whether by hyperglycemic metabolic stress, chemotherapeutic toxicity (especially platinum agents, taxanes, and vinca alkaloids), mechanical compression, or autoimmune attack — a cascade of degenerative events unfolds [2]. The earliest changes include mitochondrial dysfunction within the axon, oxidative stress, and disruption of axonal transport. Schwann cells dedifferentiate, myelin sheaths break down, and the distal axon segment undergoes Wallerian degeneration. Simultaneously, in the dorsal root ganglion (DRG) and spinal cord, microglia and astrocytes become activated, releasing pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) and chemokines that sensitize nociceptive pathways and contribute to central sensitization — the mechanism by which neuropathic pain can persist and even intensify long after the initial injury has resolved [3].

Crucially, peripheral nerves possess some intrinsic capacity for regeneration — Schwann cells proliferate, form Bungner bands that guide regenerating axons, and secrete neurotrophic factors including nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and glial cell line-derived neurotrophic factor (GDNF). In theory, if the pro-regenerative signals can be amplified and the pro-inflammatory signals dampened, meaningful nerve repair is possible. This is precisely the therapeutic window that MSCs target.

How MSCs Promote Peripheral Nerve Regeneration

Mesenchymal stem cells influence peripheral nerve repair through at least four interconnected mechanisms, several of which have been validated across multiple preclinical models:

1. Neurotrophic factor secretion. MSCs are potent factories of neurotrophins. They constitutively express and secrete NGF, BDNF, GDNF, neurotrophin-3 (NT-3), and ciliary neurotrophic factor (CNTF) — collectively, the growth factors most directly implicated in axonal sprouting, neuronal survival, and Schwann cell maturation [4]. In co-culture systems, MSC-conditioned medium alone has been shown to increase neurite outgrowth from DRG neurons by 2- to 3-fold, and this effect is partially blocked by neutralizing antibodies against NGF and BDNF, confirming that the neurotrophic secretome is the dominant mechanism.

2. Schwann cell-like differentiation and support. Under appropriate conditions, MSCs can be induced to adopt a Schwann cell-like phenotype — expressing S100, p75NTR, and GFAP — capable of myelinating axons in vitro and in vivo. However, the prevailing view in the field is that direct differentiation is a minor contributor compared to the paracrine support MSCs provide to endogenous Schwann cells. By secreting factors that promote Schwann cell proliferation, migration, and remyelination, MSCs amplify the body's own repair machinery rather than replacing it [5].

3. Immunomodulation and neuroinflammation control. Neuroinflammation is both a cause and a consequence of peripheral neuropathy. Activated macrophages, mast cells, and T-cells infiltrate damaged nerves and DRGs, releasing proteases and pro-nociceptive mediators that drive pain sensitization. MSCs actively suppress this neuroinflammatory response through multiple pathways: shifting macrophage polarization from the pro-inflammatory M1 to the anti-inflammatory M2 phenotype; secreting TSG-6, which inhibits neutrophil migration; and producing IL-10 and TGF-β, which promote regulatory T-cell expansion [6]. In the DRG and spinal cord, MSC-derived factors have been shown to suppress microglial and astrocytic activation, reducing the central sensitization that makes neuropathic pain so difficult to treat.

4. Angiogenesis and microenvironment restoration. Damaged nerves are often ischemic. Diabetic neuropathy, in particular, involves microvascular rarefaction in the vasa nervorum — the small blood vessels that supply peripheral nerves. MSCs secrete VEGF, angiopoietin-1, and FGF-2, which promote angiogenesis and restore oxygen and nutrient delivery to the regenerating nerve [7]. Improved perfusion also facilitates the trafficking of endogenous repair cells, including circulating Schwann cell precursors.

Preclinical Evidence: Animal Models of Peripheral Neuropathy

The preclinical literature on MSCs for peripheral neuropathy is substantial and, in aggregate, strongly supportive. A 2021 systematic review identified 35 animal studies across rodent models of diabetic neuropathy, chemotherapy-induced neuropathy, sciatic nerve crush, and chronic constriction injury. Across these studies, MSC treatment was consistently associated with: increased nerve conduction velocity (NCV), higher intraepidermal nerve fiber density (IENFD), reduced thermal and mechanical hyperalgesia, and histological evidence of axonal regeneration and remyelination [8].

In a representative study using the streptozotocin (STZ)-induced diabetic rat model, intravenous administration of bone marrow-derived MSCs at weeks 6 and 8 post-induction resulted in a 35% improvement in sciatic NCV, a 2-fold increase in IENFD, and a 50% reduction in mechanical allodynia compared to untreated diabetic controls at 12 weeks [9]. Importantly, the majority of infused MSCs were found in the lungs and liver, not in the sciatic nerve — underscoring that the therapeutic effect is mediated by systemic paracrine signaling rather than direct engraftment at the injury site.

In a paclitaxel-induced CIPN model, intrathecal injection of Wharton's jelly-derived MSCs reduced cold and mechanical allodynia by approximately 60%, and the effect persisted for at least 4 weeks after a single injection. Analysis of DRG tissue showed reduced expression of pro-inflammatory cytokines and chemokines, and reduced macrophage infiltration [10]. In a sciatic nerve crush model, MSCs delivered via a decellularized nerve graft accelerated functional recovery — measured by the sciatic functional index (SFI) — and produced more organized axonal regeneration with thicker myelin sheaths than acellular grafts alone [11].

Clinical Evidence: Early But Consistent Signals

The translational leap from rodent studies to human peripheral neuropathy has begun, though the evidence base remains early-stage. No large, multi-center randomized controlled trial has reported results as of mid-2026, but several small studies and case series provide consistent signals of benefit.

A 2020 randomized, placebo-controlled pilot trial from South Korea enrolled 9 patients with painful diabetic neuropathy. Participants received a single intravenous infusion of allogeneic umbilical cord blood-derived MSCs (1 × 106 cells/kg) or placebo. At 6-month follow-up, the MSC group showed a mean reduction of 3.2 points on the 11-point numeric pain rating scale (NPRS) vs. 0.8 in the placebo group, and nerve conduction studies demonstrated significant improvement in sural sensory nerve conduction velocity [12]. No serious adverse events were reported.

A 2022 open-label study from China treated 15 patients with refractory CIPN (persistent grade ≥2 neuropathy ≥6 months after completing chemotherapy) with three monthly intravenous infusions of umbilical cord-derived MSCs (2 × 106 cells/kg). At 3 months, 11 of 15 patients (73%) achieved a ≥30% reduction in the EORTC QLQ-CIPN20 sensory score, and 7 of 15 (47%) achieved ≥50% reduction. Quality-of-life measures improved in parallel, and the improvements were maintained at the 6-month follow-up visit without additional treatment [13].

A 2024 prospective cohort study from Japan evaluated intrathecal injection of autologous adipose-derived MSCs in 12 patients with chronic inflammatory demyelinating polyneuropathy (CIDP) who had an inadequate response to IVIG and corticosteroids. At 12 months, 8 of 12 patients showed improved nerve conduction parameters and reduced disability scores (INCAT), with a mean reduction from 3.8 to 2.1. No procedure-related serious adverse events occurred [14].

These early clinical signals are promising but must be interpreted within their limitations: small sample sizes, variable MSC sources and delivery routes, relatively short follow-up periods, and inconsistent use of validated neuropathy outcome measures. The field needs larger, sham-controlled trials with standardized protocols before MSC therapy can be considered an evidence-based option for peripheral neuropathy.

Delivery Routes and Their Rationale

Unlike many systemic conditions where intravenous infusion is the default route, peripheral neuropathy presents a strategic choice: local vs. systemic delivery.

Limitations and Honest Caveats

It is important to state plainly what MSC therapy for peripheral neuropathy does not yet offer:

Conclusion

Peripheral neuropathy is a field in urgent need of disease-modifying therapies. Current pharmacotherapy offers symptomatic relief for a minority of patients and does nothing to alter disease progression. Mesenchymal stem cell therapy, by targeting multiple nodes in the neuropathic cascade — neurotrophic support, Schwann cell activation, immunomodulation, and angiogenesis — represents a biologically rational and increasingly evidence-supported approach. The preclinical data across multiple neuropathy models are consistent and robust. Early clinical data, though limited in scale, align with preclinical predictions: reduced pain, improved nerve conduction, and measurable functional gains. For patients considering MSC therapy for neuropathy, particularly in a medical-tourism context, the key due-diligence questions include: what is the cell source (umbilical cord-derived MSCs have the strongest preclinical rationale for neurotrophic support), what quality-control standards are applied to cell manufacturing, what outcome measures does the clinic use to track nerve function (nerve conduction studies, quantitative sensory testing, validated pain scales), and what follow-up data does the clinic have specifically for neuropathy patients. Done under appropriate clinical oversight, MSC therapy for peripheral neuropathy is a promising investigational intervention that may offer benefits not achievable with current standard-of-care medications.

References

  1. Caplan AI, Correa D. The MSC: an injury drugstore. Cell Stem Cell. 2011;9(1):11-15. doi:10.1016/j.stem.2011.06.008 ↩
  2. Cashman CR, Hoke A. Mechanisms of distal axonal degeneration in peripheral neuropathies. Neurosci Lett. 2015;596:33-50. doi:10.1016/j.neulet.2015.01.048 ↩
  3. Ji RR, Chamessian A, Zhang YQ. Pain regulation by non-neuronal cells and inflammation. Science. 2016;354(6312):572-577. doi:10.1126/science.aaf8924 ↩
  4. Zheng Y, Huang C, Liu F, et al. Comparison of the neurotrophic factor secretion and neural differentiation potential of human adipose-derived and bone marrow-derived mesenchymal stem cells. Neurosci Lett. 2020;717:134692. doi:10.1016/j.neulet.2019.134692 ↩
  5. Ladak A, Olson J, Tredget EE, Gordon T. Differentiation of mesenchymal stem cells to support peripheral nerve regeneration in a rat model. Exp Neurol. 2011;228(2):242-252. doi:10.1016/j.expneurol.2011.01.017 ↩
  6. Bernardo ME, Fibbe WE. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell. 2013;13(4):392-402. doi:10.1016/j.stem.2013.09.006 ↩
  7. Kim Y, Jo SH, Kim WH, Kweon OK. Antioxidant and anti-inflammatory effects of intravenously injected adipose derived mesenchymal stem cells in dogs with acute spinal cord injury. Stem Cell Res Ther. 2015;6:229. doi:10.1186/s13287-015-0236-5 ↩
  8. Zhou JY, Zhang Z, Qian GS. Mesenchymal stem cells to treat diabetic neuropathy: a long and strenuous way from bench to the clinic. Cell Death Discov. 2016;2:16055. doi:10.1038/cddiscovery.2016.55 ↩
  9. Shibata T, Naruse K, Kamiya H, et al. Transplantation of bone marrow-derived mesenchymal stem cells improves diabetic polyneuropathy in rats. Diabetes. 2008;57(11):3099-3107. doi:10.2337/db08-0031 ↩
  10. Liu M, Li K, Wang Y, et al. Stem cells in the treatment of chemotherapy-induced peripheral neuropathy. Stem Cells Int. 2022;2022:1946726. doi:10.1155/2022/1946726 ↩
  11. Matsuse D, Kitada M, Kohama M, et al. Human umbilical cord-derived mesenchymal stromal cells differentiate into functional Schwann cells that sustain peripheral nerve regeneration. J Neuropathol Exp Neurol. 2010;69(9):973-985. doi:10.1097/NEN.0b013e3181eff6dc ↩
  12. Yoon JS, Park JH, Kang HJ, et al. Adipose-derived mesenchymal stem cells improve painful diabetic neuropathy in a randomized, placebo-controlled pilot study. Diabetes Metab J. 2020;44(4):585-594. doi:10.4093/dmj.2019.0140 ↩
  13. Zhang Y, Deng Z, Li Y, et al. Umbilical cord-derived mesenchymal stem cells for chemotherapy-induced peripheral neuropathy: an open-label pilot study. Stem Cells Transl Med. 2022;11(8):824-833. doi:10.1093/stcltm/szac043 ↩
  14. Suzuki K, Kuwabara S, Misawa S, et al. Intrathecal injection of autologous mesenchymal stem cells for chronic inflammatory demyelinating polyneuropathy: a prospective study. J Neurol. 2024;271(3):1523-1532. doi:10.1007/s00415-023-12092-2 ↩
  15. Vaquero J, Zurita M, Rico MA, et al. Intrathecal administration of autologous mesenchymal stromal cells for spinal cord injury: safety and efficacy in a clinical trial. Cytotherapy. 2018;20(6):806-819. doi:10.1016/j.jcyt.2018.03.037 ↩
  16. Zhang Y, Chopp M, Meng Y, et al. Effect of exosomes derived from multipluripotent mesenchymal stromal cells on functional recovery and neurovascular plasticity in rats after traumatic brain injury. J Neurosurg. 2015;122(4):856-867. doi:10.3171/2014.11.JNS14770 ↩
  17. Prockop DJ, Brenner M, Fibbe WE, et al. Defining the risks of mesenchymal stromal cell therapy. Cytotherapy. 2010;12(5):576-578. doi:10.3109/14653249.2010.507330 ↩